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A B S T R A C T
The Osteocyte, recognized as a major orchestrator of osteoblast and osteoclast activity, is the most important key
player during bone remodeling processes. Imbalances occurring during bone remodeling, caused by hormone
perturbations or by mechanical loading alterations, can induce bone pathologies such as osteoporosis. Recently,
the active fraction of parathormone, PTH (1-34) or Teriparatide (TPTD), was chosen as election treatment for
osteoporosis. The effect of such therapy is dependent on the temporal manner of administration. The molecular
reasons why the type of administration regimen is so critical for the fate of bone remodeling are numerous and
not yet well known. Our study attempts to analyze diverse signaling pathways directly activated in osteocytes
upon TPTD treatment. By means of gene array analysis, we found many molecules upregulated or downregulated
in osteocytes. Later, we paid attention to Wisp-2, a protein involved in the Wnt pathway, that is secreted by
MLO-Y4 cells and increases upon TPTD treatment and that is able to positively influence the early phases of
osteogenic differentiation. We also confirmed the pro osteogenic property of Wisp-2 during mesenchymal stem
cell differentiation into the preliminary osteoblast phenotype. The same results were confirmed with an in vivo
approach confirming a remarkable Wisp-2 expression in metaphyseal trabecular bone. These results highlighted
the anabolic roles unrolled by osteocytes in controlling the action of neighboring cells, suggesting that the
perturbation of certain signaling cascades, such as the Wnt pathway, is crucial for the positive regulation of bone
formation.
1. Introduction
The bone tissue is a dynamic tissue that constantly undergoes
modifications in response to physiological and pathological alterations
(Hadjidakis and Androulakis, 2006; Raggatt and Partridge, 2010; Sims
and Walsh, 2012), through bone remodeling (i.e. coupled bone re-
sorption and bone formation). The bone cell population consists of two
distinct lineages: the osteogenic lineage and the osteoclastic lineage.
The maintenance of normal bone structure is driven by the intercellular
cross-talk that occurs among bone cells. As proposed by many authors
(R. A. Dodds et al., 1993; Marotti and Palumbo, 2007; Skerry et al.,
1989a,b) and largely demonstrated by Bonewald (2011) and Naka-
shima (Nakashima et al., 2011) osteocytes are considered the me-
chanosensors of bone (Bertacchini et al., 2017; Maycas et al., 2015;
Nakashima et al., 2012) and are actively involved in orchestrating the
function of both bone-forming osteoblasts and bone-resorbing osteo-
clasts. However, the role of osteocytes in osteoblast regulation, under
both physiologic and pathologic conditions, is not fully characterized.
Several lines of evidences indicate that osteocytes affect osteoblast
differentiation and bone deposition in various ways: for example,
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osteocytes regulate osteogenic response through IL-6 production via the
STAT3 and ERK signaling pathway (Hao et al., 2017). Moreover, os-
teocytes subjected to Pulsating Fluid Flow stimulate the differentiation
of osteoblasts in vitro via soluble factors such as TGF-β (Vezeridis et al.,
2006). Of note, recently it has been shown that osteocytes can be
considered as a source of anabolic factors such as Wnt1, able to speed
up osteoblastogenesis by triggering Wnt signaling in osteoblasts (Joeng
et al., 2017). It is also well known that osteocytes are a source of os-
teoprotegerin, the potent inhibitor of RANKL, that mediates the in-
hibition of bone resorption, but conversely they are also the producers
of Sclerostin, the most important anti-anabolic regulator of bone for-
mation by osteoblasts (Pietrzyk et al., 2017; Tatsumi et al., 2007;
Weinstein et al., 2011; Xiong et al., 2014). During the last decade, in
order to regulate the process of bone remodeling in osteoporotic pa-
tients, PTH (1-34), also known as TPTD, has been used as an anabolic
drug (Bellido et al., 2013; Giannotti et al., 2013; Riek and Towler,
2011). The anabolic effects of parathormone involve a rapid increase in
osteoblast differentiation and bone formation due to its ability to pro-
mote proliferation of osteoprogenitor cells, to inhibit osteoblast apop-
tosis and to activate lining cells in becoming active osteoblasts (Jilka,
2007; Kim et al., 2012). The effect of such therapy is dependent on the
type of administration, in fact it has been largely demonstrated that a
short administration of TPTD increases bone mass but a long adminis-
tration leads to an increased bone resorption. The molecular reasons
why the type of administration regimen is so critical for the fate of bone
remodeling are not well known. It has been proven that the short ad-
ministration of PTH (1-34) induces osteoblast hyperplasia, increases
osteoblast survival and augments their ability to differentiate and to
induce matrix mineralization. On the contrary, long term treatment
with PTH (1-34), leads to the increment of osteoclast numbers and to
the increase of their activity during bone resorption (Guimarães et al.,
2013; Neer et al., 2001; Osagie-Clouard et al., 2017; Poole and Reeve,
2005; Sugiura et al., 2015). The molecular mechanisms occurring in
osteocytes during treatment with PTH (1-34) are poorly known; reports
published so far contradict each other, thus the activity of this hormone
on osteocytes has not yet been elucidated as well as its ability to
modulate some signaling pathways (Iida-Klein et al., 2005). In fact, the
role of the Wnt signaling pathway (the most important pathway acti-
vated in bone tissue) in the mechanical adaptation of bone, has been
studied predominantly in osteoblasts but not in osteocytes, and it is still
unclear whether osteocytes can produce Wnt in response to different
stimuli. The Wnt canonical signaling pathway affects cellular processes
by regulating β-catenin levels and its subcellular localization (Angers
and Moon, 2009; Mao et al., 2001). Upon binding of extracellular Wnt
to LRP5/6 and frizzled co-receptor complex, Dishevelled (Dsh) is acti-
vated, causing Axin recruitment to the membrane and inactivation of
glycogen synthase kinase-3β (GSK-3β) that induces, in turn, the stabi-
lization and accumulation of β-catenin in the cytoplasm (Bertacchini
et al., 2018). Stabilized β-catenin translocates to the nucleus and acti-
vates transcription. Physiological responses result in the increased ex-
pression of Wnt pathway and Wnt/β-catenin target genes including
Wnt10B, SFRP1, cyclin D1, FzD2, Wisp-2, and connexin. Among these,
it is particularly interesting and not well investigated Wisp-2, that is a
member of the Wnt1 inducible signaling pathway protein subfamily,
which belongs to the connective tissue growth factor (CTGF) family. It
may play an important role in modulating bone turnover; in particular,
it: 1) promotes the adhesion of osteoblast cells, 2) inhibits the binding
of fibrinogen to integrin receptors and 3) inhibits osteocalcin produc-
tion. This notwithstanding, Wisp-2 role in osteocyte-mediated signaling
is unknown (MacDonald et al., 2009) (Robinson et al., 2006). There-
fore, the current study is aimed to clarify the role of the osteocyte in the
changes induced by TPTD administration and will attempt to identify
the molecular differences that occur between the various effects (i.e.
fast or retard) of drug administration. For the first time, our data in-
dicate the osteocytes as producers of Wisp-2, as a molecule with a great
osteogenic power able to modulate the activity of the neighboring cells,
such as osteoblast or bone lining cells. Through this mechanism, we
focus our attention on one of the possible ways by which the osteocytes
may regulate the differentiation of mineralized tissues when exposed to
TPTD, thereby emphasizing one of the possible important functional
roles that this cell type has in bone remodeling and, more generally, in
skeletal metabolism.
2. Materials and methods
2.1. Cell lines culture
Murine Long bone Osteocyte Y4 (MLO-Y4) were provided by Prof.
Lynda Bonewald (IU School of Medicine - Indiana University,
Indianapolis) and were cultured on collagen pre-coated (GIBCO) tissue
culture plates and grown at 37 °C, 5% CO2, (95% air), using DMEM
(Euroclone) containing ribonucleosides, deoxyribonucleosides, and L-
glutamine, supplemented with 5% FBS (Euroclone), 5% CS (Euroclone)
and penicillin/streptomycin at 100 U/ml. Cells were initially thawed
and plated in 6-well plates at a concentration of 150.000 cells/well and
then subcultured once they reached 80% of confluence. MLO-Y4 cells
were cultured for different times (6, 9 or 12 h) with and without 10 nM
of TPTD (Eli Lilly, USA). At the end of treatment, cells were collected,
washed in PBS and stored at −20 °C. In parallel, the conditioned
medium from samples were collected and stored at −80 °C.
The murine IDG-SW3 osteoblast cell line was also obtained by Prof.
Lynda Bonewald. Cells were plated at 1 × 104 cells/cm2 and cultured
as previously described (Woo et al., 2011). These cells are immortalized
with a temperature sensitive T-antigen that is induced by interferon
gamma (IFN-γ), therefore they proliferate under permissive conditions
(33 °C in α-MEM with 10% FBS, 100 U/ml penicillin, 50 μg/ml strep-
tomycin) and 50 U/ml IFN-γ on type I collagen-coated plates. IDG-SW3
cells were cultured under proliferative conditions and when the cul-
tures reached confluence, the medium was replaced with osteogenic
differentiation medium (α-MEM with 10% FBS, 100 U/ml penicillin,
50 μg/ml streptomycin, 50 μg/ml ascorbic acid and 4 mM β-glycer-
ophosphate) without IFN-γ and with the addition of MLO-Y4 condi-
tioned medium in a ratio of 1:5. Cells were cultured at 37 °C and the
medium was changed every three days. Viability of MLO-Y4 cells
treated with TPTD at different concentrations was determined by the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-
based colorimetric assay. The absorbance was read at OD = 570 nm.
Mesenchymal Stem cells were kindly provided by Prof. Massimo Do-
minici (UNIMORE, Modena, IT) and were cultured in α-MEM plus 100
U/ml penicillin, 50 μg/ml streptomycin, 2.5% of Human Platelet Lysate
and 0.2% of Heparin. Osteogenic differentiation medium was the same
used for IDG-SW3 cells.
2.2. Real-time RT-PCR
Reverse transcription was performed with First-strand cDNA
Synthesis kit (Origene) using aliquots of total RNA extracted for mi-
croarray analysis. The cDNA samples were diluted to 20 ng/μl and the
amplifications were done using the Sens Mix SYBR Master Mix
(Origene).
Osteoprotegerin primers were: For 5′-TGGCACACAGTGATGAAT
GCG-3′, Rev 3′-GCTGGAAAGTTTGCTCTTGCG-5’; RUNX2 primers
were: For 5′- TTAATCCACAAGGACAGA-3′ Rev 3′-GTAAGACTGGTCA
TAGGA-5’. SOST primers were For 5′- TGAGAACAACCAGACCAT-3′,
Rev 3′- ACATCTTTGGCGTCATAG-5’; WISP-2 primers were: For
5′-TGTGACCAGGCAGTGATG-3′, Rev 5′-AGTGACAAGGGCAGAAAGT-3′
GADPH primers were For 5′-GGCATTGCTCTCAATGACAA-3′; Rev:
5′-ATGTAGGCCATGAGGTCCAC-3′. The primers were used at the con-
centration of 0,5 μM. The thermal cycling conditions were 50 °C for
2 min followed by an initial denaturation step at 95 °C for 10′, 45 cycles
at 95 °C for 30″, 60 °C for 30″ and 72 °C for 30”. The experiments were
carried out in triplicate for each data point. The relative quantification
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in gene expression was determined using the 2ΔΔCt method (Livak and
Schmittgen, 2001). By means of this method, we obtained the fold
changes in gene expression normalized to an internal control gene
GAPDH, and relative to each line (calibrator).
2.3. Gene expression
The total cellular RNA was isolated from the samples previously
collected using RNeasy RNA isolation kit (Qiagen, Hilden, Germany)
following the manufacturer's recommendations. Disposable RNA chips
(Agilent RNA 6000 Nano LabChip kit, Agilent Technology, Waldbronn,
Germany) were used to determine the concentration and purity/in-
tegrity of RNA samples using Agilent 2100 bioanalyzer. cDNA synth-
esis, biotin-labeled target synthesis, GeneChip® Mouse Genome 430 2.0
arrays hybridization, were performed according to the standard pro-
tocol supplied by Affymetrix (Affymetrix, California, USA). The amount
of transcript mRNA (signal) was determined by the MAS 5.0 absolute
analysis algorithm. All expression values for the genes in the MAS 5.0
absolute analyses were determined by using the global scaling option.
Alternatively, probe level data were converted to expression values
using robust multi-array average (RMA) procedure. Perfect match va-
lues were background adjusted, normalized using invariant set nor-
malization and log transformed. The RMA-generated data were up-
loaded onto GeneSpring software version 7.2 using the log 2
transformation procedure. Supervised analyses were performed using
the analysis of variance (one-way ANOVA) test (Welch ANOVA at a
confidence level of 0.05) with the Benjamini and Hochberg correction
of the false discovery rate, and using dChip Compare Sample procedure.
2.4. Western blot procedure and ELISA assay
Cells were collected and diluted in Lysis buffer (50 mM Tris-Cl, pH
7.4, 150 mM NaCl, 1% NP40, 2 mM EDTA, Protease Inhibitor Cocktail).
Proteins extracted were quantified with Bradford assay. SDS-PAGE was
performed according to Laemmli's procedure. Next, gels were blotted
onto nitrocellulose membranes subsequently incubated overnight at
4 °C with the following primary antibodies (all from Santa Cruz
Biotechnology, USA): anti-Pleiotropin (rabbit polyclonal, 1:250); anti-
Connective Tissue Growth Factor/CTGF (rabbit polyclonal, 1:250);
anti-Wisp-2 (rabbit monoclonal, 1:250); anti-Serpine1/PAI-1 (rabbit
polyclonal, 1:250), anti-cathepsinK/CTSK (rabbit polyclonal, 1:250),
anti-Actin (rabbit polyclonal,1:250), anti-active β-catenin (Merck-
1:2000).
Then, the membranes were incubated with a solution containing
1:2000 dilution of horseradish peroxidase (HRP)-conjugated secondary
antibody (DakoCytomation, Denmark). Target bands were visualized
using a mix of peroxidase solution plus a luminol enhancer solution
(WesternSure™ PREMIUM Chemiluminescent substrate). Result acqui-
sition and band densitometric analysis (represented by arbitrary units,
AU), were performed using the C-DiGit® Blot Scanner (LI-COR
Biosciences, NE, USA) and the Image Studio Lite 5.0 software (LI-COR
Biosciences, NE, USA). All values were compared to respective nor-
malized control levels. Analysis of proteins secreted in conditioned
medium was obtained by centrifugation at 3000 rpm for 1 h at 4 °C in
Amicon® Centrifugal Filter Devices and run in SDS-PAGE in equal
amount of volume.
Wisp-2 Elisa assay was performed based on the manufacturer's in-
structions provided by mouse Wisp-2 Elisa kit (Fine Test).
Table 1
Experimental workflow.
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2.5. Immunofluorescence
MLO-Y4 cells, grown on glass coverslips, were fixed in 4% paraf-
ormaldehyde at 4 °C for 20’, blocked in 4% BSA-PBS and incubated with
primary antibody Wisp-2 overnight at 4 °C. Coverslips were next wa-
shed with PBS and incubated with fluorescence-labeled secondary an-
tibodies (Thermo Scientific) for 1 h at room temperature. Slides were
washed and mounted with DABCO 10% solution and observed with a
Nikon E600 fluorescence microscope equipped with a digital camera.
All the images shown in this paper are representative of at least 3 in-
dependent experiments carried out under the same conditions. Images
from immunofluorescence studies were processed using Adobe
Photoshop CS 8.0 software (Adobe Systems, San Jose, CA, USA).
2.6. Alizarin red and ALP assay
The IDG-SW3 cells were cultured in 6-well plates at 105 cells/cm2
and cultured in proliferative media until they reached confluence, after
that the medium was switched to differentiation medium and changed
every three days. Media collected from MLO-Y4 cells obtained after
treatment with TPTD for 6, 9 and 12 h, were diluted in the differ-
entiation medium for IDG-SW3 cells. After 7, 14 and 21 days of os-
teogenic differentiation, the media were removed and the cell mono-
layers were gently washed 3 times with PBS. The cells were fixed in
10% buffered formalin for 10 min at 4 °C. After this time, fixative so-
lution was removed, cultures were washed in PBS and plates were
stored in PBS at 4 °C until sample processing. PBS was removed from
the stored plates and the cell layer was stained with 2% Alizarin-S
(Sigma-Aldrich, St Louis, MO, USA) at ~ pH 4.2 for 5’. Cell preparations
were washed with PBS to eliminate non-specific staining. To quantify
calcium deposition, the dye was removed from the monolayer by the
addition of 10% cetylpyridinium chloride solution until all the dye had
been drawn from the monolayer. A volume of 200 μl of the solution (in
duplicate) was transferred to a clean 96-well plate. Optical density was
measured by spectrophotometry at 570 nm, using 10% cetylpyridinium
chloride as a blank reference. All values were compared to respective
normalized control levels. The differentiation of IDG-SW3 cells was
evaluated as a function of ALP activity after 5 days. ALP activity was
assessed using an Alkaline Phosphatase Assay Kit (Colorimetric, Abcam,
USA, ab83369) according to the manufacturer's instructions. Briefly,
cells were grown on 6-well plates at a density of 1,5 × 105 cells per
well. The medium was replaced after 24 h by α-MEM containing 10%
FBS, 50 μg/ml ascorbic acid and 4 mM β-glycerophosphate (osteogenic
medium) to induce osteoblast differentiation. Cells were collected from
each treatment group and homogenized with assay buffer. The homo-
genized cellular lysate was then centrifuged at 13,000 g for 15 min to
remove insoluble cellular debris. Afterward, ALP activity was de-
termined with respect to the release of p-nitrophenol from p-
Fig. 1. A: MTT assay to measure cell viability (at 570 nm) of MLO-Y4 cells cultured for 24 h and treated for 6, 9 and 12 h with Teriparatide 10 nM and 1 μM. B-C:
Total mRNA was extracted from MLO-Y4 cells treated with Teriparatide 10 nM for the indicated times and RUNX2 and Osteoprotegerin mRNAs were amplified by
specific primers. Fold change variation was calculated. The data are representative of three independent experiments. The error bars show ST-DEV. Student T-test was
performed. ***p < 0,005.
A. Smargiassi, et al. Molecular and Cellular Endocrinology 513 (2020) 110817
4
nitrophenyl phosphate substrate: an aliquot of supernatant was col-
lected from each sample and added into the pre-labeled 96-well plate
with subsequent addition of 50 μl of 5 mM pNPP solution into each
well. The 96-well plates were then incubated at 25 °C in the dark for
60 min followed by the addition of 20 μl of stop solution into each well.
Optical density was measured at 390 nm using a Thermo Scientific
Appliskan™ plate reader (Thermo Fisher Scientific, 168 Third Avenue,
Waltham, MA, USA).
2.7. Experimental animals
Three-month-old Sprague Dawley male rats (n = 9) were purchased
from Charles River Laboratories (Calco, Lecco, Italy). At the time of
arrival, all rats were housed individually in single cages, to better check
food intake of each rat, and maintained under laboratory controlled
conditions (22 ± 1 °C, 55–60% humidity, 12 h light:12 h dark). After
seven days of acclimation to housing conditions, the rats were rando-
mized into three groups of 3 animals each (Fig. 1), indicated as follows.
Group 1 (control): fed normal diet and natural water ad libitum for 8
weeks. Group 2: fed calcium-deprived diet and distilled water ad li-
bitum for 4 weeks and successive normal diet restoration and natural
water ad libitum for 4 weeks; group 3: fed calcium-deprived diet and
distilled water ad libitum for 4 weeks and successive normal diet re-
storation and natural water ad libitum for 4 weeks with concomitant
administration of PTH (1-34) 40 μg/kg/day. The calcium-deprived diet
is a casein-based synthetic diet containing a very low amount of cal-
cium (0.04% Ca). PTH (1-34) was supplied by Eli Lilly and Company
(Indianapolis, USA), solubilized in saline (40 μg/mL) and sub-
cutaneously injected in a volume of 100 μL/100gr body weight per rat.
2.8. Immunohistochemical and histomorphometrical analysis
Immediately after euthanasia, the right femur of each animal was
removed, deprived of soft tissues, fixed in sodium phosphate-buffered
(PBS) 4% paraformaldehyde pH 7.4, and decalcified in 10% EDTA so-
lution for 30 days. Bones were then washed with PBS, dehydrated in
graded ethanol, and embedded in paraffin. Femur distal metaphyseal
trabecular bones were longitudinally cut with a Leica SP 1600 diamond
saw microtome cutting system (Leica SpA, Milan, Italy) to obtain 4 μm
thick sections. For immunohistochemical analyses the 3 tissue sections
from each sample were permeabilized with 0.3% Triton X-100, blocked
for intrinsic peroxidase activity with 3% hydrogen peroxide for 10 min,
Fig. 2. A-B-C: Gene array was performed on MLO-Y4 cells treated with Teriparatide 10 nM for 6 and 9 h. The comparison between control and treated samples (C6 vs
T6 - C9 vs T9 - T6 vs T9) were shown in the heat maps. D: Bar chart showing the most important genes involved in bone processes. Y-AXIS shows the fold change
variation between T6 and T9 samples. E: Bar chart showing the most important genes involved in bone processes. Y-AXIS shows the fold change variation between C6
vs T6 and C9 vs T9 samples.
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and processed for heat-mediated antigen retrieval with Tris-EDTA
(10 mM Tris Base, 1 mM EDTA Solution, 0.05% Tween 20, pH 9.0).
Then, the slides were blocked in 10% normal serum with 1% BSA for
two h at room temperature and incubated with primary antibody
(AM31932PU-N WISP2 ACRIS) at 4 °C for 16 h. For detection of Wisp-2,
the sections were incubated with secondary antibody anti-rabbit-HRP
(Thermo Scientific) and the binding of peroxidase-conjugated sec-
ondary antibodies was detected with a DAB kit (Vector Lab,
Peterborough, United Kingdom). For histomorphometrical analysis,
after paraffin embedding, three sections (4 μm) were obtained from
each sample and stained with Hematoxylin & Eosin (H&E). Slides were
deparaffinized by means of two changes of xylene for 5 min each, hy-
drated through a graded series of alcohol (100%, 95%, 80% and 70%)
for 5 min each and rinsed first in tap water and then, in deionized water
1 min each. After dehydratation procedure, the slides were stained in
Carazzi hematoxylin solution (DiaPath C0203), rinsed in tap water,
stained in alcoholic 0,5% eosin Y (DiaPath C0353) and rinsed in deio-
nized water 1 min each. After dehydration through a graded series of
alcohol (70%, 80%, 95% and 100%) for 5 min each and an incubation
in xylene for 10 min, each slide has been mounted using DPX mounting
solution (06522 Sigma Aldrich).
Stained sections were evaluated with Axiophot (ZEISS) microscope
equipped with a DS-Fi3 camera (Nikon) and processed with NIS-
Elements D 5.11.00 software (Nikon). WISP-2-positive cells on the
trabecular bone area were counted (N/area expressed in percentage
value) as demonstrative of WISP-2 expression. The extent of the surface
of prismatic osteoblast laminae was measured with respect to the me-
taphyseal trabecular surfaces (Ob.S/BS expressed in percentage value)
as indicative of osteogenesis occurrence.
2.9. Statistical analysis
Data are expressed as means of duplicate biological experiments.
Within each group (control, 6, 9 and 12 h treatments), differences were
tested using a one-way analysis of variance (ANOVA), with a p-value of
0.05 to consider the differences as statistically significant.
Student–Newman Keuls post-tests were employed to assess differences
between groups. All values are reported as the mean ± standard de-
viation (SD). T-student test was applied with p < 0.05. Data were
analyzed by using Prism 5 (Graphpad Software Inc., La Jolla, CA).
3. Results
3.1. Gene expression profiling of MLO-Y4 cell line upon Teriparatide
treatment
The osteocyte-like cell line (MLO-Y4) was selected for the study
since it shows a good expression of most of the typical osteocyte dif-
ferentiation markers. To explore a specific gene signature for TPTD
treated cells, we conducted a gene array experiment. In order to select
the concentration of TPTD that did not affect cell viability, MLO-Y4
were cultured for 24 h and treated for 6, 9 and 12 h with two different
drug concentrations, 10 nM and 1 μM, respectively. At the end of the
treatments, cell viability was monitored by MTT assay: the results
showed good tolerance of MLO-Y4 cells to the drug at any concentra-
tion used; no differences in terms of proliferation were shown (Fig. 1A),
therefore in order to restrict eventual side effects the lowest con-
centration was selected to perform further experiments.
In order to confirm whether TPTD was been efficacious, a time
course experiment was performed. MLO-Y4 cells were treated with
TPTD at 10 nM for 6, 9 and 12 h and the mRNA of the well-known
osteoclastogenesis inhibitory factor, Osteoprotegerin (OPG), was mon-
itored by quantitative PCR. As expected, the OPG level was increased
upon 6 h, then it dropped to the levels of untreated cells upon 9 and
12 h (Fig. 1B).
In parallel, the mRNA levels of RUNX2, a key transcription factor
associated with osteogenic differentiation, were analyzed. The results
Fig. 3. A: SDS-PAGE and immunoblotting analyses of 10 μg of MLO-Y4 protein extracts (as indicated). B: Optical density measurements. Statistical analysis made by
Student T-test.
Fig. 4. Relative expression of Wisp2 mRNA: total mRNA was extracted from
MLO-Y4 cells treated with Teriparatide 10 nM for the indicated times and
WISP-2 mRNA was amplified by specific primers. The data are representative of
three independent experiments. The error bars show ST-DEV. Student T-test
was performed. ***p < 0,005.
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turned out to be in line with the detected OPG levels, indicating a great
induction of RUNX2 upon TPTD 6h treatment, with a decreasing tran-
scription upon 9 and 12 h (Fig. 1C). Next, in order to investigate the
molecular mechanisms activated by TPTD in ML0-Y4 cells, a basal gene
expression analysis was performed after 6 and 9 h of treatment. A huge
amount of data was obtained and analyzed statistically with Anova test
(data not shown). The transcriptomes of drug treated samples (either
for 6h and 9h) showed variations, suggesting that the drug affects the
whole genome layout.
The comparison between treated samples (T6 vs T9) showed a
consistent differential gene expression of more than 4-fold (log ratio
2.0) for 40 genes shown in Fig. 2C. The fold change, mentioned above,
was kept intentionally high to restrict the field and avoid possible bias.
Differences between control and treated samples were shown with low
variations not statistically significant (Fig. 2A-B). The genes pre-
dominately involved in bone processes, such as bone erosion and bone
formation, are summarized in Fig. 2D. From the preliminary gene array
experiments, it emerged a high up-regulation of several genes involved
in bone anabolism processes; in parallel, genes involved in the bone
remodeling process were downregulated upon TPTD treatment. The bar
charts demonstrated an inversion of gene expression between the two
times selected, suggesting a possible role of these genes in a regulatory
mechanism. Next, we compared the expression of these genes in treated
samples (T6-T9) versus control samples (C6-C9) and we did not find any
significant statistical differences although there are interesting trends
(2E). (See Table 1)
3.2. Wisp-2 expression analysis in MLO-Y4 osteocytes
In order to validate the results of the gene array and to verify pre-
cisely the different expression of some genes, protein levels of CTGF,
PTN, CTSK, PAI-1 and WISP-2 were evaluated by western blot.
Fig. 5. A: Immunofluorescence images showing the localization of WISP-2 in cultured MLO-Y4 cells treated with Teriparatide 10 nM for 6 h. Magnification is 25 x. B:
The number of GFP positive cells (expressed as percentage value) was calculated on 5 different fields and it was normalized to the number of total cells stained with
DAPI. We counted as positive, all cells that exhibited detectable fluorescence; cells that did not express GFP had no fluorescence.
Fig. 6. Immunofluorescence images showing: A the localization of active β-Catenin in cultured MLO-Y4 cells treated/untreated with Teriparatide 10 nM for 6 h; B
probed proteins (as indicated) from 20 μg of nuclear extracts resolved in SDS-PAGE. Magnification is 60X.
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Intentionally, a further continuous time of 12 h of treatment was se-
lected in order to ensure complete translation between mRNA and
protein (Fig. 3A and B). We found that, all proteins followed the pre-
dicted expression by gene array, though the delta differences were not
always maintained, probably due to several mechanisms of protein
synthesis and protein degradation.
Considering the importance of Wisp-2 as a regulatory element
during adipocyte differentiation processes and the quantitative differ-
ences between control samples and TPTD-treated samples, the attention
was focused on Wisp-2 protein to analyze in detail its localization and
signaling.
To confirm the content of Wisp-2 upon TPTD treatment on osteo-
cytes MLO-Y4 cells, we monitored the expression of Wisp-2 mRNA with
specific primers. By means of quantitative qPCR we confirmed that
Teriparatide was able to speed the level of Wisp-2 mRNA at 6 h; then it
decreased consistently upon 9 h and 12. (Fig. 4).
By means of immunofluorescence, we monitored Wisp-2 localiza-
tion and we recorded an increase of fluorescence positive cells related
to Wisp-2 inside the cytosol upon 6 h of TPTD treatment (Fig. 5A and
B). Therefore, we asked about the possible signaling mechanisms
downstream TPTD, able to increase the amount of Wisp-2 in MLO-Y4
cells.
It is well known that TPTD is an active fraction of PTH hormone
that, following the link with its receptor, induces β-catenin stabiliza-
tion. β-catenin is an intermediate of WNT-pathway and upon stabili-
zation in the cytoplasm, it translocates to the nucleus, interacts with
TCF/LEF promoter and induces transcription of several genes involved
in cell proliferation such as cyclin D1, c-myc, Axin and Wisp-1.
Therefore, we asked whether also in our model TPTD was able to in-
duce β-catenin nuclear translocation. By immunofluorescence analysis,
we confirmed a clear staining of β-catenin in the nucleus and by wes-
tern blot we monitored the increase of active non-phosphorylated β-
catenin in nuclear extracts of cells treated with TPTD compared to
untreated cells (Fig. 6A and B).
Since it is known that Wisp-2 is a glycosylated secreted protein, we
tested the presence of Wisp-2 in MLO-Y4 medium. Upon TPTD treat-
ment, we collected medium from MLO-Y4 cells treated/untreated with
TPTD and we analyzed the presence of Wisp-2 in the medium. By means
of western blot, we detected Wisp-2 protein, either in whole cell lysates
either in media obtained by MLO-Y4 treated or not with the drug for
6 h. Next, we quantify Wisp-2 by Elisa Assay, confirming that Wisp-2 is
secreted at higher level in media obtained by cells treated with TPTD
(Fig. 7A and B).
3.3. Conditioning of IDG-SW3 osteoblasts differentiation
To analyze if direct effect mediated by osteocyte-secreted-Wisp-2
occurs during the osteoblast to late osteocyte differentiation, we mon-
itored by functional assays the differentiation of IDG-SW3 cells upon
conditioning of their differentiation medium, firstly with medium ob-
tained by MLO-Y4 osteocyte cells and secondly with Wisp-2 re-
combinant protein. As a first step, we analyzed the effect of MLO-Y4
cells medium (treated with TPTD for 0, 6, 9 and 12 h) during IDG-SW3
differentiation. Therefore, we maintained IDG-SW3 cells in osteogenic
differentiation medium conditioned with medium from ML0-Y4 cells
and we stopped the differentiation at 7 days (late osteoblast phenotype)
at 14 days (early osteocyte phenotype) and at 21 days (late osteocyte
phenotype). The results shown in panel (Fig. 8A–F) demonstrated that
only at 7 days of IDG-SW3 differentiation there was a statistical sig-
nificant difference between cells maintained in normal differentiation
medium T0 compared to IDG-SW3 maintained in conditioned medium
T6 and T9, suggesting a positive role of ML0-Y4 osteocyte medium
treated with Teriparatide TPTD during osteogenic differentiation.
Since we hypothesized that the positive role induced by osteocyte
ML0-Y4 conditioned medium treated with TPTD was attributed to
Wisp-2 secreted protein, we conditioned the IDG-SW3 osteogenic dif-
ferentiation (only in the first step at 7 days) with Wisp-2 recombinant
protein. Data obtained by Alizarin red and ALP functional assays were
very similar and demonstrated a strong and concentration-dependent
Wisp-2 effect in increasing the mineralization process during osteoblast
differentiation (Fig. 9A and B).
In order to verify whether this effect was specific for Wisp-2, we
repeated the experiments using Wisp-2 recombinant protein complexed
with a neutralization antibody. As expected, the increase of miner-
alization induced by Wisp-2 was completely abrogated upon the ad-
diction of the specific antibody (Fig. 9C).
To deeply analyze Wisp-2 ability to speed the osteogenesis process,
we analyzed by real time PCR and Western blot the expression levels of
some typical markers such as Sclerostin SOST, RUNX2 and DMP1, de-
monstrating an increment of these factors in cells conditioned by Wisp-
2 (Fig. 10). Moreover, since we noted that the main effects induced by
osteocyte medium on IDG-SW3 differentiation were visible at the early
stage of osteogenic maturation (7 days of IDG-SW3 differentiation re-
sembling the osteoblast phenotype) our further experiments were
Fig. 7. A: Western blot analysis of MLO-Y4 cells treated or not with Teriparatide. TL total lysates (20μg), CM conditioned medium. B: Quantification of WISP-2
protein in conditioned medium by ELISA assay.
A. Smargiassi, et al. Molecular and Cellular Endocrinology 513 (2020) 110817
8
performed on mesenchymal stem cells (MSCs) induced to osteogenic
differentiation (Grisendi et al., 2011) Therefore, we cultured MSCs in a
specific osteogenic medium added with recombinant Wisp-2 protein.
Firstly, we checked weather MSCs were able to differentiate towards
the osteogenic lineage (Fig. 11A and B) and secondly we added re-
combinant Wisp-2 to the differentiation medium.
ALP and Alizarin assays demonstrated that Wisp-2 increases the
mineralization amount of interesting behavior in mesenchymal cells
induced to osteogenic differentiation for 7 and 14 days, confirming its
role in pushing the osteoblast differentiation process (Fig. 12A and B).
3.4. Wisp-2 expression and osteoblastic laminae extension in metaphyseal
trabecular bone
In order to translate in vivo our in vitro data, we evaluated Wisp-2
expression by immunohistochemistry, in metaphyseal trabecular bone
of the distal femurs of rats. We conducted this analysis on three animal
group, without/with TPTD treatment during normal diet restoration
after 1 month calcium-free diet (see M&M). The distal femurs obtained
by all the animals were analyzed for Wisp-2 expression in osteocytes
inside the metaphyseal trabecular bone. We compared the same areas
among the group and we counted only the positive osteocytes (brown
stained). The bar charts in Fig. 13 (A-B-C-D) show that the expression of
positive cells for Wisp-2 is greater in group 3 (animals treated with
TPTD) with respect to group 2 (animal untreated with TPTD), con-
firming the ability of the drug to induce an upregulation of the molecule
in the osteocyte population. This result was in line with the finding
observed by Hematoxylin and Eosin staining of the sequential sections,
where we appreciated an increase of the extension of the surface of
prismatic osteoblast laminae in group 3 comparing to group 2; the
presence, revealed by the staining, of monostratified laminae of os-
teoblast polarized in the same direction (localized at the inner surface
of the bone cavities) is a feature suggestive of active sites of bone de-
position under TPTD administration. In fact, we detected significant
higher osteoblast surface (16%) in group 3 with respect to group 2
(12%).
4. Discussion
The effect of TPTD on the osteogenesis as well as the involvement of
osteocytes and their role in bone formation has been widely discussed,
particularly in the last decade. It has already been demonstrated that
Fig. 8. IDG-SW3 were cultured in proliferating medium (T0) and in differentiating medium for 7 (A-D), 14 (B-E) or 21 (C-F) days. Where indicated, a quarter of the
differentiating medium was added to MLO-Y4 medium (CM) treated with Teriparatide for 6h (T6) and 9h (T9). The respective controls were indicated as T0
representing IDG-SW3 cells maintained in proliferating medium. Quantification of Alizarin Red (A-B-C) staining and Alkaline Phosphatase activity were measured at
405 nm; (D, E, F). ***p < 0.005, were calculated by the Student t-test.
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intermittent administration of PTH (1-34) leads to bone deposition and
bone growth, meanwhile continuous administration of PTH (1-34) ex-
erts a catabolic effect characterized by an increase of osteoclast acti-
vation and bone resorption. Our study attempt to unreveal a new mo-
lecule acting as an anabolic factor involved in speeding the osteogenic
Fig. 9. Alizarin (A) and ALP (B) assays performed on IDG-SW3 cultured in differentiating medium for 7 days (D7) in presence of recombinant Wisp-2 protein at
300 ng/ml and 600 ng/ml. C: ALP assay performed on IDG-SW3 cells differentiated for 7 days in presence of recombinant Wisp2 at 300 ng/ml and in presence of a
medium containing the complex formed by recombinant protein plus the respective neutralization antibody. Experiments were performed in triplicate.
***p < 0,005 obtained by Student T-test.
Fig. 10. IDG-SW3 were cultured in proliferating medium (CYC) and in differ-
entiating medium for 7 days (D7). Where indicated recombinant WISP-2
(300 ng/ml) and the respective neutralization antibody were added to the
medium. mRNA was extracted from the same samples described above and
SOST, RUNX2 and DMP1 were analyzed by Real Time PCR. Fold change var-
iation was calculated. The data are representative of three independent ex-
periments. T student test was performed. CYC vs D7 ***p < 0,005; D7 vs
D7 +WISP2 ###p < 0,005; D7 +WISP-2 vs D7 + anti WISP-2 ° p < 0,005.
Fig. 11. Osteogenic differentiation of MSCs. A-B Cultured cells were stained
with Alizarin Red S after 6, 10 and 13 days of differentiation to detect osteo-
genic induction. Scale bar = 50 mm. For quantification, stains were solubilized
and the absorbance was measured spectrophotometrically at 570 nm for 0.5 s
(B). Bar charts shows fold change variations of absorbance values. All analyses
were performed in triplicate. ***p < 0,005 obtained by Student T-test.
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process, observing fast and retard effects after 6, 9, and 12 h of TPTD
treatment, by analyzing the expression of two typical bone turnover
markers, osteoprotegerin and RUNX2, in MLO-Y4. As expected, osteo-
protegerin and RUNX2 mRNA levels, increased upon 6 h of treatment,
dropping upon 9 and 12 h at levels similar to the untreated condition.
Through the gene microarray technology, we showed, in a model of
osteocyte like cells MLO-Y4, a significant alteration or changes in gene
expression, induced by TPTD treatment. To avoid any possible bias,
only those genes that showed a fold change higher than four were se-
lected; this selective restriction allowed to obtain just the panel of 40
genes that showed an “inversion of expression”. The comparison be-
tween control and treatment samples, although showing a different
expression of selected genes, does not reach the statistical significance.
Our working hypothesis was that among those genes could be in-
cluded some genes related with the osteocyte cell signaling stimulated
by TPTD. This particular “inversion of expression” may suggest that
those genes could be some of the factors that may regulate the events
occurring during TPTD treatment times mimicking anabolic to cata-
bolic switch. A closer look at those 40 genes revealed that 13 of them
were already well-known to exert biological/molecular function in
bone. Among them, it was chosen to analyze by Western Blot the ex-
pression of proteins such as CTGF, PAI-1, WISP-2, CTSK and PTN.
Among these proteins, the expression of Wisp-2 showed an interesting
behavior. Wisp-2 is a member of the CCN family and a factor of the Wnt
pathway that positively regulates the osteoblast differentiation; a
marked increment of its expression level after 6 h of treatment was
observed compared to control; also, after 9 and 12 h of treatment with
TPTD, Wisp-2 expression level was comparable to the control level.
Using our original model, we showed that the fast effect of TPTD leads
to an increase in the production of the Wisp-2 protein, which can be one
of the molecular regulators able to stimulate osteoblast differentiation.
The levels of Wisp-2 protein decreased already after 9 h of treatment
and reached levels comparable to control after 12 h. Wisp-2 is a ca-
nonical Wnt ligand that regulates cell proliferation, adhesion and dif-
ferentiation, in particular secreted Wisp-2 promotes mesenchymal
precursor cell proliferation and maintains the cells in undifferentiated
state. In bone-forming osteoblasts, Wisp-2 promotes adhesion and in-
hibits osteocalcin production (Grünberg et al., 2014; Hammarstedt
et al., 2013; Ono et al., 2011). Thus, analyzing in detail the role of this
interesting protein, it emerged that not only the expression of mRNA as
well as protein of Wisp-2 were increased upon 6 h of treatment, but also
that the secreted form, detectable in the cultured osteocyte conditioned
medium, was increased upon the same time of treatment. These data
strongly suggest that secreted Wisp-2, fast induced by TPTD treatment,
could be an important factor involved in the activation of different
signaling pathways. Based on these findings, osteocyte-derived culture
medium was used to condition the osteoblast IDG-SW3 during their
differentiation. The mineralizing ability of IDG-SW3 induced to differ-
entiate, under the conditioning effects of MLO-Y4 culture medium, was
analyzed by Alizarin Red and ALP assays. Functional assay of miner-
alization brings clues on how TPTD influences osteocyte in expressing
factors that indirectly stimulate bone cell differentiation and miner-
alization. After 7 days of culture, when the phenotype of IDG-SW3 re-
sembles the early steps of osteogenic differentiation, an increase of
mineralization was observed for all the groups and it is interesting to
highlight how the longer time point (12 h), even though it was higher
respect to the control, has an opposite trend compared to the other two
time points selected (6 and 9 h). After 14 and 21 days of differentiation
(points that mimic the early and late osteocyte phenotype, respec-
tively), only the 6 h treatment was found to induce modifications sta-
tistically significant. This result is clearly in agreement with our hy-
pothesis concerning both i) indirect effects mediated by osteocytes on
osteoblast differentiation process; ii) time-dependent effect of the drug
on osteocytes. All together, these data showed an interesting behavior
expressed by the in vitro osteocyte-like cell line model MLO-Y4, treated
at different time points, during IDG-SW3 osteoblast differentiation: in
particular, it is of note that our data point out the role of secreted
factors, such as Wisp-2, in controlling the fate of osteoblast maturation.
As proof of this finding, it was recently identified by Joeng and cow-
orkers an anabolic function of osteocytes as a source of Wnt in bone
development and homoeostasis, complementing their known function
as targets of Wnt signaling in regulating osteoclastogenesis and osteo-
blastogenesis (Joeng et al., 2017).
To substantiate the interesting data obtained in vitro, regarding
WISP-2 positive role on osteogenesis, we performed im-
munoistochemical and histomorphometrical analyses in metaphyseal
trabecular bone of the distal femurs of PTH treated/untreated rats,
concerning either Wisp-2 expression or the presence/extension of os-
teoblast laminae. Both these evaluations strongly indicate that one of
the possible mechanisms controlling TPTD anabolic role, is the WISP-2
up-regulation. This datum is in line with a recent work by Ferretti and
coworkers (Ferretti et al., 2019) demonstrating that PTH(1-34) was
actively involved in enhancing bone mass recovery, particularly in
trabecular bone depleted after calcium deprivation. In the present
study, as expected, a consistent decrease (about 25.5%) of osteoblast
laminae surface in rats maintained in calcium-free diet occurs; such
decrement is partially recovered upon the TPTD administration, in fact
we found that the number of osteoblast laminae surface was increased
(about 15,15%) following the active bone deposition triggering induced
by the drug. All these data highlighted the importance of Wisp-2 pro-
duced by osteocyte population in pushing osteogenesis process. Our
results match also with the observations by Cavani and coworkers
(Cavani et al., 2017) on PTH(1-34) effects during repairing experi-
mentally drilled holes in rat femur, where the main effect of PTH(1-34)
was demonstrated to be the induction of a faster healing of the bone
lesions with respect to the injured rats that not underwent PTH
Fig. 12. A: MSCs were cultured in proliferating medium (D0) and in differ-
entiating medium for 10 days (D10) implemented with recombinant Wisp 2 at a
concentration of 150 ng/ml. At the indicated endpoints, cells were solubilized
and the Alizarin Red stain was quantified at 570 nm. B: Analysis of ALP activity
of the samples described above. The bar charts show differences expressed as
Fold change variation. Experiments were performed in triplicate. ***p < 0,005
obtained by Student T-test.
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administration.
In conclusion, the main original findings emerging from the present
work are: i) TPTD is able to induce in osteocyte model the modulation
of genes in fast or retard timing, so that while several genes are fast
affected, considerably less changes are detectable as retard effect of the
drug ii) soluble factors, such as Wisp-2, induced by the activation of
Wnt pathway in osteocytes, are crucially involved in the fate of osteo-
blast differentiation process.
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